[Medicine] there are "4 + 7" policies, and "price reduction and quantity assurance" and "starting a new business". Who are the "top leaders" of the 30 provincial drug administration?

The aftershocks of dynamic "4 + 7" and "special collection of anticancer drugs" in local enterprises include "price reduction and quantity guarantee" and "4 + 7" collection and quantity guarantee " It seems that the enterprises have reached a consensus on the price reduction of the bid winning products within 4 + 7 or other products beyond 4 + 7 In recent days, the provincial drug and equipment procurement Center released a number of batches of drugs with reduced online prices, including some products of Zhengda Tianqing and Qilu pharmaceutical On January 24, Beijing announced that some enterprises submitted supplementary application for special centralized purchase of anticancer drugs and adjusted the application for the lowest price and promised supply price in China The adjusted products mainly involve imatinib mesylate capsules of Zhengda Tianqing and gefitinib tablets under Qilu pharmaceutical The price of imatinib mesylate capsules with two specifications of Zhengda Tianqing was lowered according to the latest quotations of Shandong Province and Zhejiang Province The latest quotations of 0.1g specification conversion ratio of 60 and 12 were 586.39 yuan / box and 124.38 yuan / box, respectively, while the latest quotations of 0.25g specification conversion ratio of 10 were 498 yuan / box On January 23, Inner Mongolia issued a document announcing that 11 anti-cancer drugs had adjusted their prices Specifically, six drugs including imatinib mesylate capsule, capecitabine tablet and dasatinib tablet of Zhengda Tianqing and hydroxycamptothecin for injection of Yuanda medicine Huangshi Feiyun pharmaceutical Among them, capecitabine tablet has the largest price reduction The latest price of 0.1g specification conversion ratio of 12 is 91.2 yuan / box, with a price reduction of 53.74% It is also worth mentioning that the price adjustment of 0.1g * 60 capsules and 12 capsules of cimetinib mesylate in Inner Mongolia is 843 yuan / box and 174.44 yuan / box respectively, which is not the lowest price in China On January 17, Liaoning announced that it had received 28 applications for active price reduction of domestic anti-cancer drugs from 8 enterprises including Qilu pharmaceutical, Zhengda Tianqing, Wuhan Renfu, Jiangsu Hengrui, and 4 applications for price reduction of domestic anti-cancer drugs and restoration of Internet access Based on the enterprise application, the price of these 32 anticancer drugs will be adjusted On January 14, Shaanxi issued a public document, and Zhengda Tianqing adjusted the price limit of imatinib mesylate capsule from 872.19 yuan / box to 586.39 yuan / box The price reduction rate is 33%, which is 6% lower than the winning price of 623.82 yuan of Haosen 4 + 7 belt purchase On December 26, Anhui issued a document, and Jiangsu Hengrui pharmaceutical actively applied for the unified reduction of the provincial centralized purchase price of "dextromethoridine hydrochloride injection (2ml: 0.2mg)", which is 10 yuan lower than the 4 + 7 centralized purchase price Therefore, this practice has led many industry figures to think that Hengrui has blocked the bid winning product (dextromethomidine hydrochloride injection) of Yangzi River 4 + 7 centralized mining Because before, youmeituomiding injection of Yangzi River has applied for the implementation of the bid winning price of 4 + 7 belt quantity procurement in Gansu and Shandong, that is, the price of hanging net is 133 yuan / piece Hengrui may be the best choice to keep the market through price reduction this time On December 26, Shaanxi issued a document, and Qilu pharmaceutical actively applied for the price limit of kefitinib tablets (specification: 0.25g * 10 tablets) to be adjusted from 1585 yuan / box to 498 yuan / box, and the adjusted price limit of hanging nets was implemented on a daily basis, with a decrease of 68.6% There was a lot of uproar in the market It was obvious that Qilu pharmaceutical would not hesitate to break the reserve price and compete with AstraZeneca's winning products (gefitinib) which were collected in 4 + 7 As we all know, AstraZeneca's gefitinib tablets (250mg * 10 tablets) have been chosen by 547 yuan, with a 76% drop On this basis, Qilu pharmaceutical has lowered the price of the Internet, which is worthy of courage "Starting a new business" price reduction is the direct way for pharmaceutical companies to occupy the market, but there are also some unusual ways for enterprises, such as AstraZeneca's exclusive promotion right in mainland China to purchase zhizhikang of LVYE pharmaceutical At that time, risuvastatin of AstraZeneca was defeated by Beijing new pharmaceutical industry in the 4 + 7 centralized purchase In order to recover the situation, the enterprise immediately turned to the Chinese patent medicine market, trying to start from other drugs with the same indications with risuvastatin and compete for 30% of the market beyond 4 + 7 However.. Zhizhikang is still in the catalogue of auxiliary drugs, and DGRs payment mode is also in progress The price reduction of chemical drugs is an inevitable trend Can Chinese patent medicine be "independent"? Will the plot eventually develop as AstraZeneca imagined? rub one's eyes and wait (refer to "the horror logic behind AstraZeneca's purchase of zhizhikang" for details of the article) local new policy Liaoning issued the first 4 + 7 volume purchase and sale contract in terms of 4 + 7 centralized purchase Last week, in addition to the news of price reduction of enterprises, the first 4 + 7 volume purchase and sale contract was issued It is reported that on January 21, the office of Liaoning Provincial Leading Group for centralized procurement of medicine and medical consumables issued the notice on printing and distributing the pilot volume purchase and sale contract (model) for centralized procurement and use of drugs organized by the state In short, the provisions can be summarized as follows: in terms of the quality of the selected products, the products provided by pharmaceutical companies should be consistent with the quality at the time of bidding, and the validity period should be at least 9 months; in terms of quantity assurance, the contract mentions that the hospital has the right to select alternative varieties under special conditions; in terms of distribution According to the needs of medical institutions, pharmaceutical enterprises are required to deliver the first-aid drugs to all medical and health institutions within the specified time (24 hours) The first-aid drugs must be delivered in time according to the clinical needs, and the distribution time should not exceed 4 hours, and the normal distribution should be carried out in holidays In terms of settlement, the medical institutions should settle accounts within 30 days from the date of receiving the drugs For how to settle the payment, both parties shall negotiate on their own; for the use of the selected products, the contract also requires the medical institutions to bear the liability for breach of contract if they fail to complete the purchase volume or use the alternative products of the selected products without any reason Chongqing started to purchase and use the 4 + 7 selected products on March 1 On January 23, Chongqing Medical Insurance Bureau issued a document, saying that Chongqing will soon issue the implementation plan of national organization drug centralized purchase and use pilot and relevant supporting documents of medical insurance, requiring relevant departments and medical institutions of all districts and counties to actively do all preparations, strengthen cooperation and cooperation, form a joint force, and ensure that the purchase and use will start on March 1 That is to say, Chongqing may become the fourth city after Shanghai, Dalian and Tianjin to ask for the 4 + 7 implementation plan Hospital public welfare return! Recently, the Beijing Municipal Health and Health Commission issued a document asking public medical institutions to adhere to the public welfare, and resolutely put an end to public hospitals contracting, renting or trusting pharmacies to for-profit enterprises There is no doubt that this policy is a reflection of Beijing's response to the national top-level design, and also a key measure for Beijing to promote the outflow of prescriptions On November 26 last year, the State Health Commission and the State Administration of traditional Chinese medicine jointly issued the opinions on accelerating the high-quality development of pharmaceutical services, concerning the implementation of the deployment of "public hospitals are not allowed to contract or rent pharmacies, nor to entrust pharmacies to profit-making enterprises" This is the state's official attitude toward pharmacy trusteeship, "prohibit profitable trusteeship" Before that, Shanghai, Beijing, Shandong, Guangdong, Qinghai and Hubei have issued policies to regulate or even prohibit the custody of pharmacies It can be predicted that in 2019, the mode of pharmacy trusteeship will be "all gone" In fact, on the topic of hospitals returning to public welfare, banning the trusteeship of pharmacies is only an exploratory process of pharmaceutical reform The government's reform of public hospitals is also a transitional link According to media reports, Henan provincial health and Health Commission recently held a working conference, at which it was pointed out that public hospitals should speed up the pace of reform in 2019, but not reform Public hospitals in all cities and counties that have been reformed should be recovered, and those that cannot be recovered should be newly built to ensure that public hospitals become the main force of basic medical and health services Summary of other local information: list of directors of drug administration of 30 provinces (municipalities directly under the central government, autonomous regions) and job information director of Jilin Drug Administration: Liu Baofang post: member of the Party group of Jilin market supervision administration department, secretary and director of the Party group of Jilin drug administration, presided over the overall work of Liaoning drug administration director of Liaoning Drug Administration: Guo Xuefeng Position: Director of Liaoning food and drug administration, Secretary of the Party group, director of the office of the provincial food safety committee, deputy director of the education, science, health and Sports Committee of the CPPCC Heilongjiang Provincial Drug Administration: Li Jun position: Director of Heilongjiang drug administration, director of Jiangxi drug administration, Shangguan Xinchen position: Director of Jiangxi drug administration, Henan Province Director of Drug Administration: Zhang Jinli post: Director of Henan drug administration, director of Hubei Drug Administration: Deng Xiaochuan post: member of the Party group of Hubei market supervision administration, secretary and director of the Party group of Hunan drug administration, director of overall work of Hunan Drug Administration: Li chiqun post: Director of Hunan Drug Administration Chongqing City Director of Drug Administration: Zhou Longhai post: member of the Party group of Chongqing municipal market supervision administration, director and Secretary of the Party group of Chongqing Municipal Drug Administration, director of Shanxi Provincial Drug Administration: Yun Yaming post: Secretary and director of the Party group of Shanxi provincial drug administration, presided over the overall work of the Provincial Bureau, director of Anhui provincial drug administration under the administration of policies and regulations: Wu Lihua post: Secretary and director of the Party group Director of drug administration of Guangxi Zhuang Autonomous Region: Wen Dongxu Title: member of the Party group of market supervision administration of Guangxi Zhuang Autonomous Region, Secretary of the Party group of drug administration of Guangxi Zhuang Autonomous Region, director of Guizhou Drug Administration: Liao Changhui Title: Deputy Director of Guizhou market supervision administration (Guizhou intellectual property Bureau), director of Guizhou drug administration Yunnan Province Director of Drug Administration: Liu Benjun Title: Secretary and director of the Party group, presided over the overall work of the provincial bureau director of Shaanxi Drug Administration: Zhang Xiaoning Title: Secretary and director of the Party group of Shaanxi drug administration, presided over the overall work director of Gansu Drug Administration: Song Baocai Title: member of the Party group of Gansu market supervision administration, secretary and director of the Party group of Gansu drug administration In charge of the overall work of the drug administration of Qinghai province director of the drug administration of Qinghai Province: Li Xiaodong Title: Director of the drug administration of Qinghai province director of the drug administration of Xinjiang Uygur Autonomous Region Zhang Yuxiang Title: Secretary of the Party group of the drug administration of Xinjiang Uygur Autonomous Region director of the drug administration of Ningxia Autonomous Region director: Wang Shengli Title: Secretary and director of the Party group of Ningxia Hui Autonomous Region drug administration, director of Sichuan Drug Administration: Zhang Dazhong Title: member of the Party group of Sichuan market supervision administration, first-class inspector, director and Secretary of the Party group of Sichuan drug administration, director of Inner Mongolia Drug Administration: Yang Fengyi Title: director of Inner Mongolia Drug Administration, Tianjin city Director of SFDA: Guo Chengming Title: member of the Party group of Tianjin market supervision and Administration Committee, director and Secretary of the Party group of Tianjin drug administration, in charge of the overall work of SFDA director of Hainan Drug Administration: Jia Ning Title: member and deputy director of the Party group of Hainan market supervision and administration, secretary and director of the Party group of Guangdong Drug Administration Director of Drug Administration: Luo Wenzhi Title: alternate member of the 12th Guangdong Provincial Committee, director and Secretary of the Party group of the Standing Committee of Shenzhen Municipal People's Congress, Secretary of the Party group of Guangdong market supervision administration, director and Secretary of the Party group of Guangdong Drug Administration, director of Shandong Drug Administration, guidunshan Title: member of the Party group of Shandong market supervision administration, Shandong Drug Administration